Core Insights - The company reported a revenue of 1.569 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 23.7% [1] - The profit attributable to equity shareholders was 498 million RMB, up 24.6% compared to the previous year [1] - The company proposed an interim dividend of 0.33 RMB per share [1] Revenue Breakdown by Product Series - The nephrology product series saw a sales increase of approximately 28.0%, with the flagship product, Uremic Granules, maintaining its market leadership [1] - The women's and children's product series experienced a sales growth of about 17.5%, becoming the second-largest revenue contributor [1] - Sales of medical imaging contrast agents grew by approximately 22.0% [1] - The bone injury product series recorded a sales increase of 2.1% [1] - The dermatology product series saw a sales growth of 19.7% [1] - The liver and gallbladder product series experienced a sales increase of 4.6% [1] - Other pharmaceuticals recorded a sales growth of 5.4% [1] - Overall sales revenue growth was attributed to the company's ongoing efforts to expand product markets and develop sales networks across the country [1] Gross Profit and Margin - The company's gross profit for the first half of 2025 was 1.209 billion RMB, an increase of approximately 27.6% compared to 948 million RMB in the same period of 2024 [2] - The average gross margin for the first half of 2025 was approximately 77.1%, up 2.4 percentage points from 74.7% in the previous year, primarily due to a decrease in the procurement prices of traditional Chinese medicine raw materials [2]
康臣药业(01681)发布中期业绩 股东应占溢利4.98亿元 同比增加24.6% 皇牌产品尿毒清维持市场领先地位